Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for rare stomach disorder in japanese study

NCT ID NCT05214768

Completed Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called CC-93538 (Cendakimab) in 48 Japanese adults and adolescents with eosinophilic gastroenteritis, a condition where certain white blood cells build up in the digestive tract causing pain and other symptoms. The trial was randomized and placebo-controlled, meaning some participants got the drug and others got a dummy treatment. The main goal was to see if the drug could reduce the number of these cells in gut biopsies and improve symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CC-93538 (Cendakimab)

What this could lead to

If successful, this could provide a new treatment option to control eosinophilic gastroenteritis, reducing inflammation and symptoms.

What could go wrong

This is a completed Phase 3 trial with only 48 participants, all Japanese. Results may not apply to other populations, and the drug may not show significant benefit over placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GASTROENTERITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Digestive System Diseases digestive system disorder Eosinophilic enteropathy eosinophilic gastroenteritis gastroenteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOSINOPHILIC GASTROENTERITIS

Contacts and locations

Locations

  • Local Institution - 001

    Setagaya-ku, Tokyo, 157-8535, Japan

  • Local Institution - 002

    Osaka, 545-8586, Japan

  • Local Institution - 0025

    Tsu, Mie-ken, 514-8507, Japan

  • Local Institution - 003

    Yamagata, 990-9585, Japan

  • Local Institution - 004

    Kobe, 650-0017, Japan

  • Local Institution - 005

    Shibukawa, 377-8577, Japan

  • Local Institution - 006

    Nagoya, 454-8509, Japan

  • Local Institution - 007

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • Local Institution - 008

    Niigata, 951-8510, Japan

  • Local Institution - 009

    Nishinomiya, Hyōgo, 663-8501, Japan

  • Local Institution - 010

    Akita, 010-8543, Japan

  • Local Institution - 011

    Maebashi, 371-8511, Japan

  • Local Institution - 012

    Ōgaki, 503-8502, Japan

  • Local Institution - 013

    Nagaoka, 940-2085, Japan

  • Local Institution - 015

    Hiroshima, 734-8551, Japan

  • Local Institution - 016

    Nagasaki, 852-8501, Japan

  • Local Institution - 017

    Hirosaki, 036-8545, Japan

  • Local Institution - 018

    Kagoshima, 890-8520, Japan

  • Local Institution - 019

    Tokyo, 108-8329, Japan

  • Local Institution - 020

    Kitakyushu, 802-8561, Japan

  • Local Institution - 021

    Nagoya, 467-8602, Japan

  • Local Institution - 022

    Himeji-shi, Hyōgo, 670-8560, Japan

  • Local Institution - 023

    Sendai, Miyagi, 982-8502, Japan

  • Local Institution - 024

    Gifu, Gifu, 5011194, Japan

  • Local Institution - 025

    Tsu, Mie-ken, 514-8507, Japan